Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Interest & Investment Income (2016 - 2025)

Cumberland Pharmaceuticals' Interest & Investment Income history spans 16 years, with the latest figure at $91967.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 28.48% year-over-year to $91967.0; the TTM value through Dec 2025 reached $476748.0, up 21.27%, while the annual FY2025 figure was $476748.0, 42.55% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $91967.0 at Cumberland Pharmaceuticals, down from $131583.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $131583.0 in Q3 2025 and bottomed at $5426.0 in Q1 2021.
  • The 5-year median for Interest & Investment Income is $53625.5 (2023), against an average of $61200.8.
  • The largest annual shift saw Interest & Investment Income tumbled 81.85% in 2021 before it soared 585.1% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $6670.0 in 2021, then skyrocketed by 585.1% to $45696.0 in 2022, then soared by 115.78% to $98603.0 in 2023, then surged by 30.41% to $128590.0 in 2024, then decreased by 28.48% to $91967.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Interest & Investment Income are $91967.0 (Q4 2025), $131583.0 (Q3 2025), and $127489.0 (Q2 2025).